In 2020, Jules Moritz joined Illingworth Research Group as COO. She has more than 30 years of clinical research experience, having started at bedside as study coordinator in a major academic hospital in Philadelphia. Jules has held positions of increasing responsibility in academic research, pharmaceutical companies, and CROs. She has worked in a number of therapeutic areas, including a concentration in rare disease and pediatric research. She is committed to increasing "patient-centricity" across the biopharma therapy development cycle.